2021 Q1 Form 10-Q Financial Statement
#000156459021021318 Filed on April 28, 2021
Income Statement
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| YoY Change | ||
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $65.10M | $46.20M |
| YoY Change | 40.91% | 463.41% |
| % of Gross Profit | ||
| Research & Development | $84.01M | $69.28M |
| YoY Change | 21.26% | 71.15% |
| % of Gross Profit | ||
| Depreciation & Amortization | $282.0K | $85.00K |
| YoY Change | 231.76% | 107.32% |
| % of Gross Profit | ||
| Operating Expenses | $124.6M | $69.28M |
| YoY Change | 79.83% | 71.15% |
| Operating Profit | -$124.6M | -$98.79M |
| YoY Change | 26.12% | 103.05% |
| Interest Expense | -$21.10M | -$70.10M |
| YoY Change | -69.9% | 13920.0% |
| % of Operating Profit | ||
| Other Income/Expense, Net | $1.544M | $14.00K |
| YoY Change | 10928.57% | -105.53% |
| Pretax Income | -$183.7M | -$168.8M |
| YoY Change | 8.8% | 233.6% |
| Income Tax | $0.00 | |
| % Of Pretax Income | ||
| Net Earnings | -$183.7M | -$168.8M |
| YoY Change | 8.79% | 233.81% |
| Net Earnings / Revenue | ||
| Basic Earnings Per Share | -$2.29 | |
| Diluted Earnings Per Share | -$2.319M | -$2.29 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 75.32M | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $723.7M | $646.7M |
| YoY Change | 11.91% | 124.39% |
| Cash & Equivalents | $265.4M | $417.9M |
| Short-Term Investments | $458.2M | $228.8M |
| Other Short-Term Assets | $50.00M | $25.70M |
| YoY Change | 94.55% | 164961.01% |
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | ||
| Other Receivables | ||
| Total Short-Term Assets | $773.6M | $672.4M |
| YoY Change | 15.05% | 116.53% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $7.077M | $15.70M |
| YoY Change | -54.92% | 1408.07% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $6.909M | $800.0K |
| YoY Change | 763.63% | 392.78% |
| Total Long-Term Assets | $36.53M | $16.50M |
| YoY Change | 121.39% | 110.86% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $773.6M | $672.4M |
| Total Long-Term Assets | $36.53M | $16.50M |
| Total Assets | $810.1M | $688.9M |
| YoY Change | 17.6% | 116.39% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $4.158M | $3.100M |
| YoY Change | 34.13% | -73.98% |
| Accrued Expenses | $69.40M | $44.93M |
| YoY Change | 54.46% | 511.91% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $6.200M | |
| YoY Change | ||
| Total Short-Term Liabilities | $83.67M | $50.70M |
| YoY Change | 65.03% | 148.69% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $386.2M | $144.6M |
| YoY Change | 167.08% | 2058.21% |
| Other Long-Term Liabilities | $288.6M | $234.6M |
| YoY Change | 23.02% | 99758.68% |
| Total Long-Term Liabilities | $674.8M | $379.2M |
| YoY Change | 77.95% | 161308.41% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $83.67M | $50.70M |
| Total Long-Term Liabilities | $674.8M | $379.2M |
| Total Liabilities | $758.5M | $429.9M |
| YoY Change | 76.43% | 359.3% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$1.094B | |
| YoY Change | ||
| Common Stock | $8.000K | |
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $51.66M | $259.0M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $810.1M | $688.9M |
| YoY Change | 17.6% | 116.39% |
Cashflow Statement
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$183.7M | -$168.8M |
| YoY Change | 8.79% | 233.81% |
| Depreciation, Depletion And Amortization | $282.0K | $85.00K |
| YoY Change | 231.76% | 107.32% |
| Cash From Operating Activities | -$153.3M | -$108.3M |
| YoY Change | 41.5% | 204.69% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $484.0K | $435.0K |
| YoY Change | 11.26% | -50.29% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | -$146.3M | -$227.4M |
| YoY Change | -35.68% | |
| Cash From Investing Activities | -$146.8M | -$227.9M |
| YoY Change | -35.59% | 25940.46% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | $381.6M | |
| YoY Change | 247.13% | |
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 1.632M | 403.3M |
| YoY Change | -99.6% | 171.71% |
| NET CHANGE | ||
| Cash From Operating Activities | -153.3M | -108.3M |
| Cash From Investing Activities | -146.8M | -227.9M |
| Cash From Financing Activities | 1.632M | 403.3M |
| Net Change In Cash | -300.1M | 66.91M |
| YoY Change | -548.44% | -40.25% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$153.3M | -$108.3M |
| Capital Expenditures | $484.0K | $435.0K |
| Free Cash Flow | -$153.8M | -$108.8M |
| YoY Change | 41.38% | 198.57% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2021Q1 | us-gaap |
Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
|
true | |
| CY2021Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2021Q1 | us-gaap |
Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
|
apls:AccountingStandardsUpdate202006Member | |
| CY2021Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P5Y4M6D | |
| CY2020Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P4Y7M28D | |
| CY2021Q1 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
1552000 | |
| CY2020Q4 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
1266000 | |
| CY2020Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
26878000 | |
| CY2020Q4 | us-gaap |
Assets Current
AssetsCurrent
|
917192000 | |
| CY2020Q4 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
311869000 | |
| CY2021Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
79000 | |
| CY2021Q1 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-1582000 | |
| CY2020Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2020Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | |
| CY2020Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
3685000 | |
| CY2020Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
128327000 | |
| CY2020Q4 | us-gaap |
Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
|
358830000 | |
| CY2020Q4 | apls |
Development Derivative Liabilities Noncurrent
DevelopmentDerivativeLiabilitiesNoncurrent
|
253638000 | |
| CY2020Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
15217000 | |
| CY2020Q4 | us-gaap |
Liabilities
Liabilities
|
756012000 | |
| CY2020Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
| CY2020Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2020Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2020Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2020Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2020Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | |
| CY2020Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
76130000 | |
| CY2020Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
76130000 | |
| CY2020Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
8000 | |
| CY2020Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
1131013000 | |
| CY2020Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-117000 | |
| CY2020Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-926347000 | |
| CY2021Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
22518000 | |
| CY2020Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
17719000 | |
| CY2021Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
7077000 | |
| CY2020Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
6803000 | |
| CY2021Q1 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
6909000 | |
| CY2020Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
18855000 | |
| CY2021Q1 | us-gaap |
Assets
Assets
|
810129000 | |
| CY2020Q4 | us-gaap |
Assets
Assets
|
960569000 | |
| CY2021Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
4158000 | |
| CY2020Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
8477000 | |
| CY2021Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
69398000 | |
| CY2020Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
111935000 | |
| CY2021Q1 | apls |
Development Derivative Liabilities Current
DevelopmentDerivativeLiabilitiesCurrent
|
6212000 | |
| CY2020Q4 | apls |
Development Derivative Liabilities Current
DevelopmentDerivativeLiabilitiesCurrent
|
4230000 | |
| CY2021Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
3902000 | |
| CY2021Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
83670000 | |
| CY2021Q1 | us-gaap |
Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
|
386152000 | |
| CY2021Q1 | apls |
Development Derivative Liabilities Noncurrent
DevelopmentDerivativeLiabilitiesNoncurrent
|
268740000 | |
| CY2021Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
19909000 | |
| CY2021Q1 | us-gaap |
Liabilities
Liabilities
|
758471000 | |
| CY2021Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
| CY2021Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2021Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2021Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2021Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | |
| CY2021Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2021Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | |
| CY2021Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
80438000 | |
| CY2021Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
80438000 | |
| CY2021Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
8000 | |
| CY2021Q1 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
1147263000 | |
| CY2021Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-1620000 | |
| CY2021Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-1093993000 | |
| CY2021Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
51658000 | |
| CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
204557000 | |
| CY2021Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
810129000 | |
| CY2020Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
960569000 | |
| CY2021Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
84012000 | |
| CY2020Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
69282000 | |
| CY2021Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
40579000 | |
| CY2020Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
29504000 | |
| CY2020Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-98786000 | |
| CY2021Q1 | apls |
Loss On Conversion Of Debt
LossOnConversionOfDebt
|
39487000 | |
| CY2021Q1 | apls |
Interest Expense Nonoperating
InterestExpenseNonoperating
|
4175000 | |
| CY2020Q1 | apls |
Interest Expense Nonoperating
InterestExpenseNonoperating
|
3919000 | |
| CY2021Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
79000 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
1394000 | |
| CY2021Q1 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-1582000 | |
| CY2021Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-1503000 | |
| CY2021Q1 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
162258000 | |
| CY2021Q1 | apls |
Adjustments To Additional Paid In Capital Forfeiture Of Accrued Interest In Exchange Of Convertible Notes
AdjustmentsToAdditionalPaidInCapitalForfeitureOfAccruedInterestInExchangeOfConvertibleNotes
|
1668000 | |
| CY2021Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
2588000 | |
| CY2021Q1 | us-gaap |
Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
|
-956000 | |
| CY2021Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
16439000 | |
| CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-183659000 | |
| CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
34229000 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
381458000 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
1674000 | |
| CY2020Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
9294000 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
1394000 | |
| CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-168822000 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-230000 | |
| CY2020Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
258997000 | |
| CY2021Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-183659000 | |
| CY2020Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-168822000 | |
| CY2021Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
16439000 | |
| CY2020Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
9294000 | |
| CY2021Q1 | apls |
Loss On Conversion Of Debt
LossOnConversionOfDebt
|
39487000 | |
| CY2021Q1 | us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
-17084000 | |
| CY2020Q1 | us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
-68406000 | |
| CY2021Q1 | apls |
Forfeiture Of Accrued Interest In Exchange Of Convertible Notes
ForfeitureOfAccruedInterestInExchangeOfConvertibleNotes
|
1668000 | |
| CY2021Q1 | apls |
Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
|
112000 | |
| CY2020Q1 | apls |
Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
|
57000 | |
| CY2021Q1 | us-gaap |
Depreciation
Depreciation
|
282000 | |
| CY2020Q1 | us-gaap |
Depreciation
Depreciation
|
85000 | |
| CY2021Q1 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
360000 | |
| CY2020Q1 | apls |
Amortization Of Discounts For Convertible Notes Net Of Financing Costs
AmortizationOfDiscountsForConvertibleNotesNetOfFinancingCosts
|
1994000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
5819000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
3004000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
4242000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
671000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
-11946000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
460000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-4170000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-5237000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-42802000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-9991000 | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-153314000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-108349000 | |
| CY2021Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
484000 | |
| CY2020Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
435000 | |
| CY2021Q1 | us-gaap |
Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
|
171281000 | |
| CY2020Q1 | us-gaap |
Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
|
227419000 | |
| CY2021Q1 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
25000000 | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-146765000 | |
| CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
567045000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-227854000 | |
| CY2020Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
381593000 | |
| CY2020Q1 | apls |
Proceeds From Development Derivative Liability
ProceedsFromDevelopmentDerivativeLiability
|
20000000 | |
| CY2021Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
2588000 | |
| CY2020Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
1674000 | |
| CY2021Q1 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
956000 | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
1632000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
403267000 | |
| CY2021Q1 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
-1611000 | |
| CY2020Q1 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
-152000 | |
| CY2021Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-300058000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
66912000 | |
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
351985000 | |
| CY2021Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
266987000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
418897000 | |
| CY2021Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
265435000 | |
| CY2020Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
417881000 | |
| CY2021Q1 | us-gaap |
Restricted Cash
RestrictedCash
|
1552000 | |
| CY2020Q1 | us-gaap |
Restricted Cash
RestrictedCash
|
1016000 | |
| CY2021Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
266987000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
418897000 | |
| CY2021Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
6893000 | |
| CY2020Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
3829000 | |
| CY2021Q1 | us-gaap |
Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
|
126129000 | |
| CY2021Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of Organization and Operations </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Apellis Pharmaceuticals, Inc. (the “Company”) is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company was incorporated in September 2009 under the laws of the State of Delaware and has its principal office in Waltham, Massachusetts.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s operations since inception have been limited to organizing and staffing the Company, acquiring rights to product candidates, business planning, raising capital and developing its product candidates. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks common in the biotechnology industry including, but not limited to, raising additional capital, development by its competitors of new technological innovations, its ability to successfully complete preclinical and clinical development of product candidates and receive timely regulatory approval of products, market acceptance of the Company’s products, protection of proprietary technology, healthcare cost containment initiatives, and compliance with governmental regulations, including those of the U.S. Food and Drug Administration (“FDA”). Additionally, the Company is subject to risks arising from the Coronavirus Disease 2019 (COVID-19) pandemic, which could have adverse effects upon its business and operations, including on its ability to initiate, conduct and complete clinical trials, delay the initiation of planned and future clinical trials and could disrupt regulatory activities.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Adoption of ASU 2020-06 Debt – Debt with Conversion and Other Options (Subtopic 470-20)</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective January 1, 2021, the Company early adopted ASU 2020-06, <span style="font-style:italic;">Debt – Debt with Conversion and Other Options (Subtopic 470-20) </span>which<span style="font-style:italic;"> </span>reduces complexity in applying GAAP to certain financial instruments with characteristics of liability and equity. The ASU removes the guidance that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock. The ASU further revises the guidance to require entities to calculate diluted earnings per share for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted earnings per share when an instrument may be settled in cash or shares. The impact of the adoption of the statement increased net debt outstanding and decreased net equity by $149.7 million as of January 1, 2021. Of the $149.7 million decrease to net equity, $16.0 million was recorded to retained earnings. See Note 5, Long Term Debt for additional information.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Convertible Notes Exchange </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="font-size:12pt;"> </span>January 2021, the Company entered into separate, privately negotiated exchange agreements to modify the conversion terms with certain holders of its convertible notes issued in September 2019 (the “2019 Convertible Notes”). Under the terms of these exchange agreements, the holders exchanged approximately $126.1 million in aggregate principal amount of 2019 Convertible Notes held by them for an aggregate of 3,906,869 shares of common stock issued by the Company. The Company also issued 69,491 shares for settlement of issuance costs paid to the Company’s advisor. The Company recognized a total loss on conversion of debt in the unaudited condensed consolidated statement of operations of $39.5 million. As of March 31, 2021, the Company held as treasury Convertible Notes the $126.1 million principal amount of exchanged notes and such notes have not been cancelled. See Note 5, Long Term Debt for additional information. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:7pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity and Going Concern </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited condensed consolidated financial statements have been prepared on the basis of the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of April 28, 2021, the date of issuance of these unaudited condensed consolidated financial statements, the Company believes that its cash and cash equivalents of $265.4 million and marketable securities of <span>$458.2<span style="font-size:12pt;"> </span></span>million as of March 31, 2021 will be sufficient to fund its operations and capital expenditure requirements for at least the next twelve months from the date of issuance of these unaudited condensed consolidated </p> <p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financial statements</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The future viability </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the Company </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">beyond that point is dependent on its ability to raise additional capital to finance its operations.</span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks common to other life science companies in the development stage including, but not limited to, uncertainty of product development and commercialization, lack of marketing and sales history, development by its competitors of new technological innovations, dependence on key personnel, market acceptance of products, product liability, protection of proprietary technology, ability to raise additional financing, and compliance with FDA and other government regulations. If the Company does not successfully commercialize any of its product candidates, it will be unable to generate recurring product revenue or achieve profitability. The Company’s plans to meet its short-term and longer-term operating cash flow requirements include obtaining additional funding. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are uncertainties associated with the Company’s ability to (1) obtain additional debt or equity financing on terms that are favorable to the Company (2) enter into collaborative agreements with strategic partners to obtain funding, and (3) succeed in its future operations. If the Company is not able to obtain the required funding for its operations, or is not able to obtain funding on a timely basis on terms that are favorable to the Company, it could be forced to delay, reduce or eliminate its research and development programs or future commercialization efforts and its business could be materially harmed. </p> | |
| CY2021Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
265400000 | |
| CY2021Q1 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
458200000 | |
| CY2021Q1 | apls |
Contract Research And Development Other Assets
ContractResearchAndDevelopmentOtherAssets
|
6100000 | |
| CY2021Q1 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
1600000 | |
| CY2020Q4 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
1300000 | |
| CY2021Q1 | apls |
Prepaid Research And Development Cost Current
PrepaidResearchAndDevelopmentCostCurrent
|
14100000 | |
| CY2020Q4 | apls |
Prepaid Research And Development Cost Current
PrepaidResearchAndDevelopmentCostCurrent
|
8000000.0 | |
| CY2021Q1 | apls |
Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
|
32586000 | |
| CY2020Q4 | apls |
Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
|
47879000 | |
| CY2020Q4 | apls |
Accrued License Fees Current
AccruedLicenseFeesCurrent
|
25050000 | |
| CY2021Q1 | apls |
Accrued Payroll Liabilities Current
AccruedPayrollLiabilitiesCurrent
|
11857000 | |
| CY2020Q4 | apls |
Accrued Payroll Liabilities Current
AccruedPayrollLiabilitiesCurrent
|
22896000 | |
| CY2021Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
24955000 | |
| CY2020Q4 | apls |
Contract Research And Development Long Term Assets
ContractResearchAndDevelopmentLongTermAssets
|
18000000.0 | |
| CY2020Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
16110000 | |
| CY2021Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
69398000 | |
| CY2020Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
111935000 | |
| CY2020Q4 | apls |
Development Derivative Liabilities Gross
DevelopmentDerivativeLiabilitiesGross
|
257868000 | |
| CY2019Q4 | apls |
Development Derivative Liabilities Gross
DevelopmentDerivativeLiabilitiesGross
|
134839000 | |
| CY2020Q1 | apls |
Minimum Payment Of Additional Funding Amount
MinimumPaymentOfAdditionalFundingAmount
|
20000000 | |
| CY2021Q1 | us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
-17084000 | |
| CY2020Q1 | us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
-68406000 | |
| CY2021Q1 | apls |
Development Derivative Liabilities Gross
DevelopmentDerivativeLiabilitiesGross
|
274952000 | |
| CY2020Q1 | apls |
Development Derivative Liabilities Gross
DevelopmentDerivativeLiabilitiesGross
|
223245000 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Description
LesseeOperatingLeaseDescription
|
The Company enters into lease agreements with terms generally ranging from 2-7 years. Some of the Company’s lease agreements include Company options to extend the lease on a month-to-month basis or for set periods for up to five years. Many of these leases also include options to terminate the leases within one year or per other contractual terms. Renewal and termination options were generally not included in the lease term for the Company’s existing operating leases. | |
| CY2021Q1 | apls |
Lessee Operating Lease Maximum Term Of Options To Terminate Lease
LesseeOperatingLeaseMaximumTermOfOptionsToTerminateLease
|
P1Y | |
| CY2021Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
22518000 | |
| CY2020Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
17719000 | |
| CY2021Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
23811000 | |
| CY2020Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
18902000 | |
| CY2021Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0776 | |
| CY2020Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0774 | |
| CY2021Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1300000 | |
| CY2020Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1000000.0 | |
| CY2021Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1588000 | |
| CY2020Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
968000 | |
| CY2021Q1 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
5675000 | |
| CY2020Q1 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
334000 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
4204000 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
5415000 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
5480000 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
4811000 | |
| CY2021Q1 | apls |
Lessee Operating Lease Liability Payments Due Year Four And Thereafter
LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereafter
|
9267000 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
29177000 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
5366000 | |
| CY2021Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
23811000 | |
| CY2021Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-1503000 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
1164000 | |
| CY2021Q1 | apls |
Minimum Percentage Of Tax Position Likelihood Of Being Realized Upon Examination By Taxing Authorities
MinimumPercentageOfTaxPositionLikelihoodOfBeingRealizedUponExaminationByTaxingAuthorities
|
0.50 | |
| CY2021Q1 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
0 | |
| CY2021Q1 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
0 | |
| CY2020Q1 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
0 | |
| CY2021Q1 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
0 | |
| CY2020Q1 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
0 | |
| CY2021Q1 | apls |
Contra Research And Development Expense
ContraResearchAndDevelopmentExpense
|
8100000 | |
| CY2020Q4 | apls |
Contract Research And Development Receivable
ContractResearchAndDevelopmentReceivable
|
43000000.0 | |
| CY2021Q1 | apls |
Contract Research And Development Current
ContractResearchAndDevelopmentCurrent
|
20000000.0 | |
| CY2020Q4 | apls |
Contract Research And Development Current
ContractResearchAndDevelopmentCurrent
|
25000000.0 | |
| CY2021Q1 | apls |
Estimated Termination Costs And Other Fees
EstimatedTerminationCostsAndOtherFees
|
3200000 | |
| CY2021Q1 | us-gaap |
Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
|
0 | |
| CY2021Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
24334000 | |
| CY2020Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
15307000 |
